Knight Therapeutics Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Samira Sakhia
- Full Time Employees
- 745
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 3400 De Maisonneuve Boulevard West Montreal QC Canada H3Z 3B8
- IPO Date
- Apr 3, 2014
- Website
- gud-knight.com
- Similar Companies
- Business
- Knight Therapeutics Inc. Knight Therapeutics Inc. (TSX: GUD) is a pan-American (ex-US) specialty pharmaceutical company that acquires, in-licenses, out-licenses, markets and commercializes innovative prescription pharmaceuticals in Canada and Latin America. Founded in 2014 and headquartered in Montreal, Quebec, the company operates through wholly-owned subsidiaries including Biotoscana Farma, United Medical and Laboratorio LKM, with presence in Canada and 10 Latin American countries such as Brazil, Colombia, Mexico, Argentina, Chile, Peru, Ecuador, Bolivia, Paraguay and Uruguay, employing over 700 people globally. Knight focuses on therapeutic areas including oncology and hematology, infectious diseases, pain and gastrointestinal, ophthalmic, women's health, urology and other specialty segments; its marketed products include Movantik for opioid-induced constipation, Probuphine for opioid dependence, Impavido for leishmaniasis, Burinex for edema, Halaven and Lenvima for cancer indications, Aloxi for chemotherapy-induced nausea, Minjuvi for relapsed or refractory diffuse large B-cell lymphoma, Qelbree for ADHD, Bijuva and Imvexxy for menopausal symptoms, Trelstar for prostate cancer, Salofalk for ulcerative colitis, Ursofalk for biliary cirrhosis, Exelon for dementia, as well as Karfib for multiple myeloma and Pemazyre for cholangiocarcinoma following recent regulatory approvals. In March 2025, Knight entered a definitive agreement to acquire the Paladin business from Endo Operations Limited for an upfront cash payment of $120 million including inventory, closing in June 2025 for approximately $107 million with potential additional contingent payments of up to US$15 million, significantly expanding its Canadian portfolio with stable cash-flow generating pharmaceuticals. In June 2025, the company entered exclusive licensing agreements with Sumitomo Pharma America for MYFEMBREE, ORGOVYX and vibegron in Canada, plus mature products, for an upfront of C$25.4 million and up to C$15.75 million in milestones, enhancing its women's health, urology and prostate cancer offerings. Most recently in October 2025, Knight closed a US$100 million secured revolving credit facility to support growth, while reporting record-high Q3 2025 revenues and Adjusted EBITDA alongside increased full-year financial guidance.
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
Knight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript
Knight Therapeutics Reports First Quarter 2026 Results
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call
Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
Knight Therapeutics (KHTRF) Expected to Announce Earnings on Thursday
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call Transcript
Knight Therapeutics Reports Third Quarter 2025 Results
Knight Announces Closing of US$100 Million Revolving Credit Facility
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
Knight Therapeutics Inc. (KHTRF) Q2 2025 Earnings Call Transcript
Knight Therapeutics Reports Second Quarter 2025 Results